The Newsroom

Investigations  /  05.29.2020

Investigation of Sorrento Therapeutics, Inc.

You Have Legal Options

Sorrento Therapeutics, Inc. (SRNE) Accused of Misleading Shareholders 

On May 15, 2020, Sorrento announced that it had discovered an antibody that had “demonstrated 100% inhibition of SARS-CoV-2 virus infection” and stated on national television “[Sorrento] want[s] to emphasize there is a cure.” Following these auspicious statements, Sorrento’s stock price soared to as high as $10.00 per share, representing a 281.7% increase from its May, 14, 2020 closing price. However, on May 20, 2020, Hindenburg Research issued a report calling Sorrento’s claims “sensational,” “nonsense,” and “too good to be true” after speaking with Mount Sinai, the company Sorrento was collaborating with, which cautioned that “nothing in medicine is 100%.” In response, Sorrento’s CEO refuted the Hindenburg report stating “when you see a virus is not infecting the healthy cell, you know you have the real deal.” Finally, on May 22, 2020, BioSpace published an article revealing that in an interview on May 21, 2020, Sorrento’s officers “insist[ed] that they did not say it was a cure” but rather that it could potentially be a cure.  On this news, Sorrento’s stock price fell to $4.93 per share, representing a 49.4% decline from its class period high of $10 per share.

If you purchased Sorrento Therapeutics, Inc. (SRNE) securities between May 15, 2020 and May 22, 2020, you have until July 27, 2020, to ask the court to be appointed lead plaintiff for the class.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns